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1. Introduction 
The challenge for the health care sector, the government, medical profession, health 
care provider, as well as for health care business manager, is to continually explore ways 
to ensure that the welfares of individual patients remain the utmost primacy and promote 
health care equity via corporate socially responsible activities. There is an essential need 
to truly embrace corporate social responsibility (CSR) and ethical principles that would 
promote equal distribution of health care resources.1 Relevant CSR activities would be 
achieved by making the most significant health problems in a given society the 
uppermost priority of health care organizations.  
2. Organizational Ethics 
a) The Moral Status of Organizations  
 
Organizational decisions are taken by the employees, with various particular roles, on 
behalf of the organization to represent its mission and purpose.  Health care organizations 
(HCO) are granted the same official rights as individuals and are treated as legal persons 
under the law. This implies that these institutions have legal obligations and moral 
obligations as well. HCO are moral agents in several senses: 
• Like individuals, they have organizational goals that are detailed in their mission 
statements.  
• Organizations act like people, but their decision-making processes are formed by 
a group of people rather than individualistic decision. 
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• Organizations, just like persons, are normatively assessed. They have moral 
responsibilities and are anticipated to meet them.  Organizations are judged on 
how well they treat their employees and how well they achieve their mission.2 
It cannot be absolutely argued that organizations are full- fledged moral agents. The 
actions of the organization depend on the individuals who collectively take decisions. 
These individuals are also accountable for organizational action. They, however, act as 
agents for the organization deriving their direction from the mission and objectives of the 
organization. In summary, organizations are moral agents and, like individuals, can be 
held morally responsible; yet, they are different than individual moral agents because 
they do not literally make choices and act.3 Therefore, institutions are exposed to several 
ethical expectations by the society.  
b) Stakeholder Theory  
 
This theory takes into account the interests and rights of the comprehensive range of 
individuals and organizations who cooperate with and are affected by business decision-
making.  It emphasizes the role of various stakeholders in the long term and success of 
the organization. This theory is important to business ethics because it recognizes many 
values and moral agency on diverse levels. A stakeholder is any individual or group of 
people whose role is essential to the survival and well-being of the organizations or 
cooperations. Stakeholders are mostly affected by the cooperation or organization and its 
activities and guide it in defining objectives and mission. Management, employees, 
shareholders, customers, suppliers, society, and the community are examples of 
stakeholders.4 
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This theory argues that the goal of any organization or company is to prosper the firm 
and all its stakeholders. It implies that profit maximization is not a problem in itself; it 
only becomes an issue if managers give profit-maximizing actions a preference over 
activities that promote the well-being of primary stakeholders, including the society. 5 
The theory challenges the arguments that a manger’s chief obligation is to maximize 
profits and encourages the firm to coordinate stakeholder interests. The father of 
stakeholder theory, R. Edward Freeman, believes that the corporations and stakeholders 
have reciprocal relationships in the sense they can affect each in terms of benefits and 
harms and in terms of duties and harms.6  
3. Corporate Social Responsibility: Past and Present 
a) Background History of CSR 
 
While CSR was broadly examined in the last forty years of the twentieth century, the 
notion that business has social responsibilities was apparent at least as early as the 
nineteenth century. In Britain, idealistic business managers, as the result of the Industrial 
Revolution, built factory towns, such as Port Sunlight (founded by William Lever in 
1888), which was planned to offer employees and their families accommodation and 
other facilities when various parts of the newly industrialized towns were slums.7 
CSR was mostly identical to philanthropy, and there was difficulty distinguishing 
business philanthropy from individual philanthropy.8 Early examples of CSR referred to 
obligations above and beyond economic and legal responsibilitie.  The 1960s saw the 
spread of the CSR notion when researchers started to focus on it and define it. 
Philanthropy was met with improvements in terms of employee as well as customer 
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relations. The following period mainly highlighted the role of management, the need to 
estimate, plan, and shape CSR as well as evaluate social performance. During the 1980s, 
a sequence of ethical disgraces affected the public view, and CSR topic was carried to the 
public and communities. In the1990s, CSR notion was highly accepted and companies 
with good reputation were known to have good CSR practices.9 Nowadays, CSR is 
known as a rising business strategy that companies are integrating into their core 
activities, plans, and operations. With such growing consideration, and despite some 
enduring unwillingness from the management to entirely embrace the model, CSR is 
predicted to further improve in strength and significance, becoming a central 
management issue of the 21st Century and ultimately a part of standard business 
practice.10 
b) CSR: Present Day 
 
Many factors including economic and social globalization, scientific and 
technological development, and better access to information emphasized the fact that 
ethical behavior and social responsibility is vital to organization’s practices. Social 
responsibility should tackle and meet other stakeholders’ interests while simultaneously 
increasing shareholders’ profits.11 Re-interpreting the view of social responsibility means 
that an organization should not only accomplish its economic and legal requirements but 
also dynamically contribute to the social good. 12  
Legal regulation is an essential condition for respectable corporate social performance 
but an inadequate one. Legislation and its application confirm the legality of management 
decisions.13 National and international law associated with social responsibility are 
already used, but law by itself is inadequate to endorse such an ethical conduct. 
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Certification of social responsibility under international norms—Social Accountability 
SA 8000 and ISO 26000 are international norms that plan to apply better work settings 
based on the principles of the International Labor Organization, the United Nations 
Convention on Children’s Rights, and the Universal Declaration of Human Rights. 14 It is 
critical for companies to adhere to a legal and ethical framework regarding business then 
manage and implement CSR initiatives and activities.15The World Business Council for 
Sustainable Development (WBCSD), a coalition of 120 international companies, asks the 
business to undertake broader duties in the social area and assert that CSR is decisively 
on the universal strategy agenda.16 The International Business Leaders Forum (IBLF), 
Business for Social Responsibility (BSR), and Business in the Community (BITC) are 
organizations that are promoting greater consideration to CSR.17  
CSR is thought of as an enduring responsibility demanding organizations to act 
ethically. Simultaneously, they should support the financial strength of the organization, 
which would ultimately improve the quality of life of employees, their families, and the 
community.18 The number of organizations that carry out a socially responsible behavior 
is greatly increasing, meaning that citizens, and investors, are deeply aware that profit 
and ethical values are compatible. Embracing a socially responsible conduct can be 
tactical worldwide, contributing to the competitiveness of a company and protecting its 
reputation and brand image.19 CSR is achieved only if a new model of corporate 
governance is put in place that uses internal mechanisms of control and takes into account 
the public and stakeholders’ accountability.20 
CSR is supported by theories that signify that organizational decisions and activities 
influence more than just stockholders. This perspective believes that the duty of a 
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manager goes beyond making wealth; it also includes guarding the welfare of the 
environment, the community, and society as a whole in which the organization 
operates.21 Carroll suggested a Pyramid of Corporate Responsibilities that had economic 
duties at the bottom of the pyramid, then legal responsibilities, then moral 
responsibilities, which meant doing what is right, just, and fair, and avoiding or 
minimizing harm to stakeholders, and finally, on the peak, philanthropic responsibilities, 
which refers to contributing to refining the quality of life in a community. 22 
4. Corporate Social Responsibility  
a) CSR Concept 
 
There are many definitions for CSR; all imply that CSR is influential to the 
achievement of a firm’s purposes, such as profit maximization, long-term success, and 
survival.  Davis argued for the importance of socially responsible decision-making. 
Johnson (1971) affirmed that social responsibility was compulsory since businesses 
needed to balance various stakeholders’ interests and benefits to confirm the 
accomplishment of several goals and long-run profit maximization. In 1973, Davis 
argued businesses and organizations will ultimately lose the power and legitimacy 
granted by society if they do not behave socially responsible. This idea gained support 
from many researchers who started to argue for a normative approach to CSR. 
Researchers emphasized that organizations and companies have moral obligations and 
have to meet the societal expectations, as they are similar to individual moral agents.23 
For the purpose of this paper, CSR is defined as a business approach that generates 
long-term shareholder value by taking up opportunities and managing risks originating 
		 8	
from socially responsible decisions.24 Early subjects in CSR conceptualization 
highlighted the fact that business volunteerism was important to accomplish social 
responsibilities duties.  Moreover, CSR was regarded as a business cost that might 
adversely impact affect the bottom line.  Nevertheless, the emerging pattern that visions 
CSR and shareholder wealth as harmonizing goals is driven and inspired by a different 
school of thought.  Drucker (1984) was the first to argue that social opportunities could 
be transformed into business opportunities. He suggested that businesses can turn social 
problems into economic benefits.25   
b) CSR and Health Care Organizations 
 
For HCOs, the new consideration for CSR should take into consideration the global 
vast poverty- related health challenges. Nowadays, society expects more from 
corporations and organizations due to hard social and economic realities. They expect 
business to have a responsibility to stakeholders, society, and future generations. Since 
these expectations are different, the business enterprise or organization should identify, 
analyze, and prioritize the stakeholder demands to establish a realistic and practical 
corporate duty. The social, health, and environmental problems facing global society 
today suggest that a more and different responsibility have been allocated to other actors, 
including corporations.26 
Many leading stakeholders in health care hold the research-based pharmaceutical 
companies accountable for the deaths of millions of people living in poverty because 
such companies retain their prices for life-saving medicines high.  These companies 
consider financial profits more important than human life. It is noteworthy to note that 
many actors are responsible for social problems, and they all share a duty to contribute to 
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society prospering. Duty refers to definite responsibilities stakeholders are bound to 
respect and follow. Each stakeholder has a particular duty depending on its role. 
However, the assigned responsibility has to be limited and definite, adapted to each 
stakeholder’s resources and role. The important responsibility of any health care 
organization or pharmaceutical company is to enlighten itself about its effect on society's 
numerous needs and objectives and to be thoughtful and responsive to the demands of 
stakeholders. Through this tactic, the business enterprise or organization will have a 
practical and defined social responsibility that is based on corporate values, resources, 
technical know-how, and enlightened leadership.27 
There are three types of CSR: 
• Required of business by society—the "must do" aspect of social responsibility. 
This aspect is required for a corporation's sustainable existence. Examples include 
the delivery of products or services in good quality and at a fair price, compliance 
with laws and regulations, employment at fair and living wages and in decent 
working conditions, profit-making, and wise strategic decisions. For 
pharmaceutical companies, which are seen as the primary drivers of globalization 
and its main beneficiaries, they are highly expected to accomplish responsibilities 
that go beyond what laws require- such as correcting vulnerabilities. Moreover, 
they are expected to aid in donations in cases of acute emergency and perform 
differential prices for patients in poor countries.28 
• Expected of business by society—the "ought to do" aspect of social 
responsibility: this is less binding than the first obligation, but it equates to "good 
corporate citizenship". Examples include extra-legal obligations like avoiding 
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questionable practices and being fair and responsive to legitimate concerns of 
fair-minded stakeholders, as well as working legitimately beyond legal 
requirements where local legal conditions do not meet enlightened standards, such 
as with regard to social and environmental conduct. This dimension relates to the 
ten principles of the United Nations Global.29 
• Desired of business by society—the "can do" aspect of social responsibility, the 
self-actualization of which justifies public praise. Examples of the "can do' 
dimension include corporate philanthropy, community and neighborhood 
programs, volunteerism, and donations. “Desirable" actions cover a dimension of 
social responsibility that is neither required by law nor by standard industry 
practice. Delivery on the "can do" norms of social responsibility will not protect a 
company whose actual operations do not comply with the law or other aspects of 
the "must do" dimension. However, this dimension can offer people substantial 
social and other advantages. Examples include: free training opportunities using 
company structure; scholarship for children in low-income groups; psychosocial 
care for employees with specific diseases;  Corporate philanthropy; expenditure 
beyond a corporation's concrete;30 HCO and pharmaceutical companies, 
possessing both financial capitals and knowledge and experience, can donate 
medications for poor people or treat disadvantaged vulnerable people.31 
5. Central Ethical Values and Obligations of Health Care 
Organizations 
a) Ethical Values of Health Care Organizations 
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Health care organizations ethics has three intertwined but distinct scopes. The first is 
the expression of the moral compass for the organization referred to its mission, vision, 
and values. The Chief Executive Officer should also play the role of Chief Ethics Officer. 
The second dimension relates to the critical ability in identifying the ethical challenges 
and solving them in methodical means. The third element relates to the practical 
implication and integration of organizational ethics through management process.32 
On one hand, compliance relates to meeting regulatory and legal requirements and it aids 
the organizations in reducing the risk of severe punishments. Such programs are 
obligatory and are usually recognized by top management. On the other hand, ethics 
programs are optional and dedicated to important standards and values. 33 Ethically 
admirable organizations must hold a deep set of values applicable to the promotion of 
health and care of the sick and must be skilled at dealing with conflicting values that arise 
in health care. Organization ethics refers to organization’s attempts in defining its core 
values and mission, seek the best possible resolution of struggles, and run its functions to 
confirm that it acts according to the defined set of values. The scarcity of resources in the 
health care sector drives organizations to set significances in a way that is both ethically 
justifiable and clinically sound.  
Madison Powers and Ruth Faden in their book, Social Justice, set up ethical motives 
why all human beings have a right to well-being. They define the six fundamental 
dimensions of well-being: health, personal security, reasoning, respect, attachment, and 
self-determination. It is proposed that governments, NGOs, and business have a 
synergistic responsibility to deliver these aspects.  Pharmaceutical companies create 
medicines and therapies to help alleviate suffering while increasing profit. 34 Yet, these 
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companies, if they are to be morally ethical according to Powers and Faden, should play 
an active part to help create access to medicine for the impoverished people around the 
globe. This could be achieved in many ways, including making new treatments for 
neglected tropical diseases (NTDs), offering free drugs to poor communities, providing 
donated goods to disadvantaged regions, offering low-priced price structures for critical 
medicines, and granting transitory patents to external companies to make life-threatening 
drugs. It is important to note that the health care sector cannot solve the underlying 
causes of poverty, however, the social circumstances for human health are more the 
accountability of global economic organizations ranging from the World Bank and IMF 
to international governments who work within this international economic structure.35 
Thus, a partnership of the pharmaceutical companies and hospitals with governments, 
international institutions, NGOs might achieve social and health equity.36 
b) Article 14: Social Responsibility and Health 
 
The Report of the International Bioethics Committee of UNESCO on Social 
Responsibility and Health has addressed this idea of social responsibility in the 
framework of health care delivery proposing a new standard in hospital governance. The 
scope of this responsible behavior	necessitates hospitals and other healthcare 
organizations to accomplish its social and market goals, based on law and general ethical 
standards. The report proposes that social responsibility should be considered a moral 
obligation to create organizational value.37 The originality and the significance of this 
article are that it openly broadens the concept of social responsibility, applying it not only 
to the private sector but also to the public sector and governments in order to fulfill the 
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full recognition and deliverance of health care as a right to everyone based on universal 
ethical principles.38 
Julian Huxley, the first Director-General of UNESCO, stated that in order to make 
science play a part in creating peace, security and human wellbeing, it was obligatory to 
correlate the uses of science to values.39 This highlights the principle of social 
responsibility and health, which aims at re-arranging bioethical decision-making in the 
direction of crucial concerns of several countries (such as access to quality health care 
and critical medicines).40 Governments aim to promote health and social development for 
their people. Progress in science and technology should also increase the access level to 
quality health care and essential drugs, nutrition, and water. Progress in science and 
research should also be associated with a progress of living conditions and the 
environment and reduction of poverty and illiteracy rates41.  Despite the increase of new 
medicines and technologies, there are many global health concerns. Thus, social 
responsibility actions will contribute meaningfully to a decrease of inequities in health, 
promote human rights, and construct social capital. However, accountability and 
commitment and the consistent performance of professional responsibilities in the chase 
of social goods are always major concerns.42 
Some recent international efforts to meet the needs of the unfortunate include 
improved health, which also was included in the eight UN Millennium Development 
Goals (MDG). This includes halving poverty, halting the spread of HIV and AIDS, and 
offering worldwide primary education. The UN concrete action plan emphasized the fact 
that extreme poverty is indicative of a globe of insecurity because poverty, inequality, 
and disease are some of the main grounds for violent struggle and civil war. The 
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Millennium project assumes that the health care sector, including hospitals and the 
pharmaceutical industry, already has the technology and know-how to solve the majority 
of the problems faced in poor and developing countries. The goal was to achieve the 
following eight goals by the year 2015:  
• Eradicate extreme poverty and hunger. 
• Achieve universal primary education. 
• Promote gender equality and empower women. 
• Reduce child mortality. 
• Improve maternal health. 
• Combat HIV and AIDS, malaria and other diseases.43 
Development organizations have confronted the pharmaceutical industry to increase 
its efforts to tackle the health disaster affecting developing countries. They reflect that a 
socially responsible company should design, plan, and implement policies on access to 
treatment for developing countries which include the five significances of pricing, patent, 
joint public-private initiatives, research and development, and the appropriate use of 
drugs. They state that critical challenges continue, chiefly the issue of pricing. Recently, 
new projects of pharmaceutical companies have a purely charitable characteristic that 
will not generate profits. Examples include the new Institute for Tropical Diseases in 
Singapore for the discovery of drugs for HIV and AIDS and other prevalent diseases. 
These companies should make alliances with public, private, NGOs, international 
organizations and civil society to address the elements of health in a globalized world 
through health research and progress.44 
6. Ethical Principles 
a) Principle of Justice 
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Thomas Pogge elaborates on the moral duty of western societies and companies to 
deliver system transformation in order to alleviate some of the world’s prevalent human 
grief.  In his book, World Poverty and Human Rights, the comments on Articles 25 and 
28 found in the United Nations Declaration on Human Rights: Everyone has the right to a 
standard of living satisfactory for both the health and well-being of himself and of his 
family, including food, clothing, housing, and medical care.45 Pogge then clarifies an 
intuitive notion examining the current globalization and interconnections that necessitate 
universal justice principles in which everyone should accept and share. Therefore, social 
justice includes the human right to health based on the idea that health is a universal 
human right; there must be worldwide access to medicines.46 Hence, pharmaceutical 
companies and healthcare organizations have a moral responsibility to provide access to 
medicine for those who cannot afford them while achieving sustainable business ends.47 
 
Justice explains how social burdens and benefits should be distributed. The 
egalitarian theories state that people should receive an equal distribution of health care.48  
Based on John Rawl’s principle of Justice, the fair opportunity is vital to justice in the 
health care field. This implies that each person, regardless of his/ her social status, should 
have equal access to a sufficient level of health care. There should be a right to a decent 
minimum49 of health care: basic health care and other health- related resources.50 
b) Principle of Beneficence 
In addition to justice principle, pharmaceutical companies and HCOs have an 
obligation to follow the principle of beneficence.  In their Principles of Biomedical 
Ethics, Beauchamp and Childress describe beneficence as not simply kindness or charity, 
but a real obligation to support others and further their genuine benefits. Beneficence 
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states that one should prevent harm, remove harm, and promote good.51 It is important to 
note that there is an embedded beneficence assumption in all health care professions; 
health education and vaccination programs. HCOs have a moral responsibility to conduct 
research into medicines that can help those in disadvantaged regions, not just profit 
driving medicine for Western conditions or lifestyle medications.52 Active social 
responsibility requires hospitals and others healthcare organization to do something 
beneficial (out of beneficence duties) and not only abiding by the law or to broad ethical 
principles. This implies that the interests and values of all stakeholders are taken into 
concern.53 
7. Common Good  
a) Pharmaceutical Corporations & Health Care Organizations 
 
Pharmaceutical corporations and HCOs contribute to the common good.  With their 
goods and services, they make different types of value added for society. For instance, 
current medicines and therapies, aid in reducing death rates and preventing/curing 
diseases. Therefore, it is argued that successful HCOs increase the quality of life of the 
sick, minimize costly hospitalization through researching, manufacture, and distribute 
drugs of high social benefits.54 HCOs should pursue their ends by contributing to their 
society. They own the know-how, vast resources, expertise, and management talent to 
solve social problems that they fully comprehend both in the developing world and in 
economically deprived communities. Creating shared value in practice by following a 
strategic approach to CSR, Porter argues that such strategic CSR efforts 
are fundamental to a company’s profitability, success, and competitive position.55 
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Therefore, HCOs with their embedded ethical values combined with their knowledge and 
resources should focus their CSR activities on solving health related issues in local and 
international communities.  
Clear and comprehensible efforts by individual actors, governments, donors, NGOs, 
and the private sector are required to act based on each party’s skills, techniques, 
knowledge, and assets. Thus, social corporate responsibility is also articulated by the 
readiness of the health care organization to cooperate with other parties. The 
pharmaceutical companies and HCO have an end that is achieved through its normal 
business activities like research, development, manufacturing, and selling pharmaceutical 
compounds to avoid premature mortality, to treat or lessen diseases, to avoid or shorten 
hospitalization, and to contribute to the quality of life of sick people.56  
The pharmaceutical industry and hospitals are heavily regulated, on national as well 
as international levels.57 This triggers much exacerbation and financial stress.58 In the 
field of health care, the ethical and socially conscious behaviors are both the community 
and professions' anticipation. CSR in the health care sector is different from CSR in other 
businesses because medicine and medical care are vital for the good being of humanity.59 
Poor individuals cannot afford expensive medications due to the market and patent 
requirements, the absence of generics, or affordable changes to patented medicines.  This 
truth has become intolerable in the society’s eyes.  In numerous polls, U.S. consumers 
rate the pharmaceutical industry as one of the most unethical businesses.60 
The health care sector, in general, is a sector where the thoughts of corporate 
commitment, liability towards patients, ethical performance and an overall responsibility 
towards society are universal. David R Brennan, CEO of Astra Zeneca says, 
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accountability is integrated into the strategy of pharmaceutical companies because of it 
significant to sustained success.61 In illustrating pharmaceutical CSR, Heal suggests 
programs run by the health care sector to respond to issues related to making drugs 
accessible at reduced prices to impoverished populations.62All the top 20 pharmaceutical 
companies have developed robust CSR initiatives and many have fundamental CSR 
teams in place. Most importantly, the pharmaceutical industry and hospitals have the 
technical know-how in medicine development and health care services, they have the 
ethical commitments of beneficence and justice to provide better development and access 
to medicines for underprivileged societies. CSR meets stakeholders’ demand, objectives 
of health care institutions, and universal ethics requirements – help lessen human 
suffering and improve the lives of people.63 
In health care, CSR means that there is an ethical obligation that requires hospitals 
and other organizations to do something beneficial to health- related issues such as 
delivering quality health care to everyone who is titled to it. Integrating social 
responsibility strategic planning and daily activities require time and effort by the 
management professionals of HCOs.64 Pharmaceutical companies and hospitals should 
tackle and meet the needs of various stakeholders and strategically focus on some.  
b) CSR and Health Care 
 
In the health care setting, a set of values should be followed such as equity in access 
to health care, universal coverage, and efficient resource allocation. Therefore, the 
implementation of a socially responsible behavior could be a vital step for a hospital to 
expand its competitiveness and to protect its external image. There should be a serious 
consideration for all stakeholders including the public and society at large: patients, 
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patient associations, NGOs, the environment, healthcare professionals, healthcare payers 
and policy makers, the government and regulatory groups.65 For example, a socially 
responsible pharmaceutical company or hospital should investigate and find which way 
to treat or carefully discard a waste product that may pollute the environment.66 
Klaus Leisinger of Novartis states that the duty of the pharmaceutical company in an 
international economy is to research, develop, and manufacture groundbreaking 
medicines that make a transformation to sick people’s quality of life, and it is their duty 
to do so in a profitable way.  No other societal actor assumes this responsibility.  
Nevertheless, several pharmaceutical companies recognize a moral duty to do more, 
whenever probable, to aid in lessening health problems of poor individuals all over the 
world.67 Small and Medium Enterprises (SMEs) in the health care sector usually adopt 
different CSR practices when compared with large corporations because they do not have 
the resources.68 However, SMEs should also pursue CSR activates in order to become 
and remain successful locally as well as in the international economy.69 Companies report 
their CSR practices to be accountable and transparent, in terms of corporate governance 
as well as environmental, social and financial sustainability.70 
Having a vigorous CSR program can help HCOs attract and maintain key talent. 
Companies and hospitals will have better social perception and community engagement. 
Surveys indicate that people not only desire to work for socially responsible firms, but 
may essentially give up a proportion of salary to do so.  For instance:  A 2009 Kelly 
Services Survey questioned around 100,000 people in 34 countries around the world.  
They found 88 % of respondents are more probable to want to work for a company that is 
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considered ethically and socially responsible.  56% say that in deciding where to work, an 
organization’s ethical status for ethical conduct is very significant.71   
Michael Porter and Mark Kramer’s view recommend companies to wisely select the 
social subjects they aim to solve, especially the ones that interconnect with their 
professional, proficiency, management talent, and know-how, arguing that corporations 
which choose social issues based on their expertise will have a greater impact on the 
social good.72 Williams and Aguilera (2008), in their comparative assessment of CSR, 
report verification in the literature regarding the impact that an occupation or an industry 
has on the type of CSR firm implements.73  
8. Corporate Social Responsibility and Competitive Advantage 
a) Examples of CSR 
 
Nonprofit hospitals have some responsibility for contributing to the general welfare 
of the community, as required by the Internal Revenue Service (IRS). Services and 
resources of nonprofit hospitals that are utilized to the advantage of groups or individuals 
who are not members of the plan itself are called community benefits. It is argued that 
community benefits form a vital part of the ethical obligations of HCOs. Many hospitals 
were established based on a charitable objective to serve the poor, and there is a long 
tradition of health-care institutions offering benefits to the surrounding community.  
Moreover, American hospitals have frequently provided free care and immunizations for 
the uninsured. In some states, community benefit system turned to be a codified effort 
rather than a voluntarily one via state laws necessitating HCOs to have shown concrete 
plans for community benefits. Moreover, it is argued that generous contributions to the 
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neighboring communities are a central obligation of all businesses. The pharmaceutical 
industry could reinterpret the notion of social responsibility by acknowledging the access 
of vulnerable populations to lifesaving medicines. Developing and enriching the local 
communities are as essential as profit maximization. Eli Lilly is one of the largest 
charitable foundations in the United States.74 
The pharmaceutical industry could reinterpret the notion of social responsibility 
by acknowledging the access of vulnerable populations to lifesaving medicines. 
Examples of CSR activities include offering drugs to disadvantaged populations, 
providing preferential pricing in the world poorest countries in an effort to aid combating 
diseases such as AIDS and malaria, supplying vaccines to international NGOs or UN 
agencies at better prices.75 Moreover, corporations should address the health and safety of 
employees at work from possibly toxic processes and products. For instance, hospitals 
should offer increased health and safety protection for technicians while working with 
radioactive substances in particular oncology treatment manufacturing procedures.76 
Other examples include: building LEED standard Green buildings, adopting 
environmentally friend practices such as energy saving processes and packaging 
reduction, 77 conserving water, and protecting the supply of clean potable water to the 
surrounding communities.78 
Philanthropy based CSR activities exemplify the pharmaceutical industry. The 
main philanthropic role should be recognized to the pharmaceutical industry is its 
entitlement to improve human life and offer treatment for diseases.79 Moreover, 
pharmaceutical companies often set up foundations in order to support, educate and better 
tackle a disease for which they offer a cure. For example, a company providing anti-
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retroviral drugs would establish a foundation that focuses on AIDS education in Africa. 
Furthermore, they also deliver humanitarian action and support to various causes, often in 
association to a product they deliver, or to help a community they work with, or a nation 
where they carry out their production process or conduct clinical research.80Additionally, 
the pharmaceutical companies usually fund research grants to students, universities, and 
educational organizations because the pharmaceutical industry is very much reliant on 
research and on the development of science through research.81 
b) The Link Between Competitive Advantage and Corporate Social 
Responsibility 
 
Strategic CSR initiatives start with a strong strategic grounding to connection an 
organization’s values to investments in social issues that can reinforce the organization’s 
competitiveness. The CSR of HCOs and pharmaceutical companies should create a 
balance between their responsibilities to add value to society and the growth of the 
enterprises. 82 Strategic CSR can be a source of opportunity and competitive advantage 
rather than a cost to the health organization and more than a moral obligation. Achieving 
both social and economic interest for the organization demands to look beyond 
community anticipations to opportunities.  Strategic CSR should integrate society, 
business, and ethical values. It necessitates the corporation to act differently from 
competitors and reap the benefits of shared value by capitalizing in social issues that 
reinforce company’s competitiveness. Characteristically, the more closely tied the CSR to 
the company’s business, the greater the opportunity to leverage the firm’s resources and 
benefit society. The most strategic CSR occurs when the cooperation adds a social 
element to its value preposition, and this provides a new edge in competitive positioning. 
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This is essentially important especially in an era where exposure to liability, consumers’ 
awareness of social problems, and government regulations are all continually 
increasing.83 These attitudes must change if companies want to leverage the social 
dimension of corporate strategy. To choose the right options for CSR, managers of HCOs 
have to be selective and construct practical and focused social initiatives and integrate 
those within their core strategies.  
9. Managers of Health Care Corporations 
a) Virtue Ethics of Managers and Leaders at Health Care Organizations 
 
Professional ethics, such as in healthcare, is an application of virtue ethics. This kind 
of ethics focuses on the moral agent and not on the results of actions taken by the moral 
agent. Virtue ethics lists good judgment as a fundamental characteristic of the moral 
agent. “Practical reasoning”, as Aristotle says, is a requirement for mental virtues, and 
this includes several virtues such as vision, experience, and other critical analysis skills.  
High moral standards of employees would provide organization’s excellence and decent 
ethical climate.84 The good character of honesty, compassion, trustworthiness, and 
devotion of high-level managers is an essential requirement for excellent ethical practice. 
However, this is not sufficient. 
Enterprises with enlightened leadership should do more than just the minimum 
obligation described by “the must” dimension in view of the global social problems of 
our times. The health care organization has to entirely realize the difficult social issues, 
then investigate methods to do good. Enlightened leaders who own sufficient courage and 
imagination, will show the right signal through an organization and into the broader 
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society. This will achieve the expectations of the society and achieve the long-term 
interests of the organization.85 These leaders must integrate CSR into the cooperation’s 
strategy through the understanding of the competitive market environment, the 
connection with the corporation goals and strengths. This is critical to achieving the long-
term goals of the organization and achieving better financial performance.86 Thus, CSR 
should be linked strongly to organizations strategic planning and monitoring process. 
This is more likely to happen if the institution has enlightened leadership combined with 
virtue ethics.  
b) Managers’ Role in Undergoing Corporate Social Responsibility Activities 
 
The healthcare industry is significantly regulated, but the continuing request for it to 
be socially responsible and ethically oriented is definite. It follows that a new 
organizational culture is considered crucial to overcoming the market failures that can 
appear in health care sector. 87 Public inquiry of business activities has boosted over the 
last years, causing more deliberation to be placed on social contribution, social 
responsibility, and the ethical performance of managers and directors. This necessitates 
health care managers to fully comprehend the conceptions around CSR.88 
HCOs face new encounters in recent societies. The deficiency of economic 
sustainability of most health care systems guided to the introduction of the innovative 
public management to certify the existence of the welfare state.89 Due to high levels of 
anxiety and poverty, the criticism against globalization, increasing acknowledgment of 
the failure of governments to resolve many social problems, and distrust of giant 
businesses, there is mounting pressure on business managers and their companies to 
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deliver broader social value. This necessitates successful management skills and 
applicable use of stakeholder engagement.90  
The health care industry is in a remarkable position because it supplies both the 
entrepreneurial power and the skill crucial in encouraging economic development. 
Nevertheless, it can often be publicly disregarded if profit maximization is noticed to be 
the leading target. When debatable settings happen in an organization, the moral 
character of management who take decisions can become the heart of speculation.91 
Patrick Maclagan considers the debate on the ethical or non-ethical character of the 
organization challenging, as these features must apply to the behavior of the members 
working at the organization or company. Consequently, the emphasis should be on its 
members, their personal values, actions, and ethical choices.92 The formal 
implementation of CSR by corporations could be connected with the altering personal 
values of managers.93 This implies that key individuals will be involved in articulating 
and applying companies' CSR policy.94 Managers’ personal beliefs and values are 
important, and should not be constrained by the values underlying the system in which 
they operate.95 
In HCOs, inaccuracies in management plans and poor leadership judgments can 
influence all stakeholders and shareholders because actions could possibly form life-
threatening consequences. Health care managers, in essence, form the structure and 
managerial support that makes the day-to-day activities of health care attainable. They 
also tend to form the ethical norms for corporations. Thus, they must have a broad 
understanding of a number of business values and ethical principles. They also need to 
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acknowledge their dual role of serving the patients and communities and making a profit, 
as this is a significant managerial capability.96 
Therefore, health care managers need ethical training as a meaningful part of their 
professional position.97 Ethical counseling may become fundamental in achieving ethical 
capability and developing capacities for good success.98 The manager’s responsibility is 
considered as a crucial one. The manager has the mission of bringing things together; of 
making them work together, of shaping opinions and leading all action.99 However, 
several factors make leadership decisions and actions morally challenged including 
increased presence of managed care and an aging population predestined to demand 
higher levels of health care than.100 
10. Conclusion 
CSR in health care applied to hospitals and pharmaceutical companies should 
promote shared values and common ethical principles in new patterns of hospital 
governance.101In the health care context, social responsibility has a broader field of 
involvement including issues related to human rights, gender equality, child labor, and 
the environment. The health care sector is rigorously anticipated to behave ethically and 
deliver treatments for all individuals. As such, it is under very tight pressures from 
policymakers, NGOs, media, and the public at large, especially that it has become very 
competitive. The importance of CSR is now well recognized in the health care sector.102 
In conclusion, CSR and organizational ethics are essential to regain vanished confidence 
of the local and international communities and win back the admiration of skeptical 
patients and doubting communities. Therefore, HCOs have to have a renewed 
commitment to ethics.103  It is important to note that benchmarking HCOs on their CSR 
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performance forms inter-business rivalry, which in turn improve CSR and leads to actual 
access to medicine practices.104 
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